Endocrinol Metab.  2020 Jun;35(2):260-271. 10.3803/EnM.2020.35.2.260.

Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus

Affiliations
  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea

Abstract

It is well known that patients with type 2 diabetes mellitus (T2DM) are at an increased risk of morbidity and mortality from atherosclerotic cardiovascular (CV) complications. Previously, the concept that diabetes mellitus (DM) is a “coronary artery disease (CAD) risk equivalent” was widely accepted, implying that all DM patients should receive intensive management. However, considerable evidence exist for wide heterogeneity in the risk of CV events among T2DM patients and the concept of a “CAD risk equivalent” has changed. Recent guidelines recommend further CV risk stratification in T2DM patients, with treatment tailored to the risk level. Although imaging modalities for atherosclerotic cardiovascular disease (ASCVD) have been used to improve risk prediction, there is currently no evidence that imaging-oriented therapy improves clinical outcomes. Therefore, controversy remains whether we should screen for CVD in asymptomatic T2DM. The coexistence of T2DM and heart failure (HF) is common. Based on recent CV outcome trials, sodium glucose cotransporter-2 inhibitors and glucagon like peptide-1 receptor agonists are recommended who have established ASCVD, indicators of high risk, or HF because of their demonstrated benefits for CVD. These circumstances have led to an increasing emphasis on ASCVD and HF in T2DM patients. In this review, we examine the literature published within the last 5 years on the risk assessment of CVD in asymptomatic T2DM patients. In particular, we review recent guidelines regarding screening for CVD and research focusing on the role of coronary artery calcium, coronary computed tomography angiography, and carotid intima-media thickness in asymptomatic T2DM patients.

Keyword

Atherosclerosis; Calcium; Coronary vessels; Carotid intima-media thickness; Risk assessment; Diabetes mellitus, type 2

Figure

  • Fig. 1 Pathogenesis of atherosclerotic cardiovascular disease and vascular complications in type 2 diabetes mellitus. AGE, advanced glycation endproducts; ROS, reactive oxygen species; eNO, exhaled nitric oxide; ASCVD, atherosclerotic cardiovascular disease.


Cited by  1 articles

Coronary Artery Calcium Score as a Sensitive Indicator of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus: A Long-Term Cohort Study
Dae-Jeong Koo, Mi Yeon Lee, Sun Joon Moon, Hyemi Kwon, Sang Min Lee, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki Won Oh, Sung Rae Cho, Young-Hoon Jeong, Eun-Jung Rhee
Endocrinol Metab. 2023;38(5):568-577.    doi: 10.3803/EnM.2023.1770.


Reference

1. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008; 26:77–82.
Article
2. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999; 100:1134–46.
3. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care. 1998; 21:1138–45.
Article
4. Bessueille L, Magne D. Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes. Cell Mol Life Sci. 2015; 72:2475–89.
Article
5. Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes. 2017; 9:434–49.
Article
6. Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018; 42:188–195.
Article
7. Xia J, Yin C. Glucose variability and coronary artery disease. Heart Lung Circ. 2019; 28:553–9.
Article
8. Liang S, Yin H, Wei C, Xie L, He H, Liu X. Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis. J Diabetes Metab Disord. 2017; 16:45.
Article
9. McClelland AD, Kantharidis P. microRNA in the development of diabetic complications. Clin Sci (Lond). 2014; 126:95–110.
Article
10. Banerjee J, Nema V, Dhas Y, Mishra N. Role of microRNAs in type 2 diabetes and associated vascular complications. Biochimie. 2017; 139:9–19.
Article
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229–34.
Article
12. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009; 26:142–8.
Article
13. Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med. 2016; 31:387–93.
Article
14. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020; 43:S111–34.
15. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation. 2015; 132:923–31.
16. McAllister DA, Read SH, Kerssens J, Livingstone S, McGurnaghan S, Jhund P, et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation. 2018; 138:2774–86.
Article
17. Liu Y, Gao G, Yang C, Zhou K, Shen B, Liang H, et al. The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int J Mol Sci. 2014; 15:10567–77.
18. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393:31–9.
Article
19. Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia. 2017; 60:2129–38.
Article
20. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013; 34:2436–43.
Article
21. Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017; 37:191–204.
Article
22. Pereira CA, Carneiro FS, Matsumoto T, Tostes RC. Bonus effects of antidiabetic drugs: possible beneficial effects on endothelial dysfunction, vascular inflammation and atherosclerosis. Basic Clin Pharmacol Toxicol. 2018; 123:523–38.
Article
23. Zhang ZY, Miao LF, Qian LL, Wang N, Qi MM, Zhang YM, et al. Molecular mechanisms of glucose fluctuations on diabetic complications. Front Endocrinol (Lausanne). 2019; 10:640.
Article
24. Lu J, Ma X, Shen Y, Wu Q, Wang R, Zhang L, et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther. 2020; 22:72–8.
Article
25. Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, et al. Protocol of a prospective observational study on the relationship between glucose fluctuation and cardiovascular events in patients with type 2 diabetes. Diabetes Ther. 2019; 10:1565–75.
Article
26. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation. 1995; 92:2157–62.
27. Yeboah J, Erbel R, Delaney JC, Nance R, Guo M, Bertoni AG, et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis. 2014; 236:411–7.
Article
28. Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004; 43:1663–9.
Article
29. Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw LJ, et al. Interplay of coronary artery calcium and risk factors for predicting CVD/CHD mortality: the CAC consortium. JACC Cardiovasc Imaging. 2020; 13:1175–86.
30. Blaha MJ, Cainzos-Achirica M, Dardari Z, Blankstein R, Shaw LJ, Rozanski A, et al. All-cause and cause-specific mortality in individuals with zero and minimal coronary artery calcium: a long-term, competing risk analysis in the Coronary Artery Calcium Consortium. Atherosclerosis. 2020; 294:72–9.
Article
31. Valenti V, Hartaigh BO, Cho I, Schulman-Marcus J, Gransar H, Heo R, et al. Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients. Circ Cardiovasc Imaging. 2016; 9:e003528.
Article
32. Min JK, Lin FY, Gidseg DS, Weinsaft JW, Berman DS, Shaw LJ, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the “warranty period” for remaining normal? J Am Coll Cardiol. 2010; 55:1110–7.
33. Min JK, Lin FY, Gidseg DS, Weinsaft JW, Berman DS, Shaw LJ, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the “warranty period” for remaining normal? J Am Coll Cardiol. 2010; 55:1110–7.
34. Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, et al. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J. 2012; 76:712–20.
Article
35. Park GM, An H, Lee SW, Cho YR, Gil EH, Her SH, et al. Risk score model for the assessment of coronary artery disease in asymptomatic patients with type 2 diabetes. Medicine (Baltimore). 2015; 94:e508.
Article
36. Celeng C, Maurovich-Horvat P, Ghoshhajra BB, Merkely B, Leiner T, Takx RA. Prognostic value of coronary computed tomography angiography in patients with diabetes: a meta-analysis. Diabetes Care. 2016; 39:1274–80.
Article
37. Beller E, Meinel FG, Schoeppe F, Kunz WG, Thierfelder KM, Hausleiter J, et al. Predictive value of coronary computed tomography angiography in asymptomatic individuals with diabetes mellitus: systematic review and meta-analysis. J Cardiovasc Comput Tomogr. 2018; 12:320–8.
Article
38. Muhlestein JB, Lappe DL, Lima JA, Rosen BD, May HT, Knight S, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014; 312:2234–43.
39. Turrini F, Scarlini S, Mannucci C, Messora R, Giovanardi P, Magnavacchi P, et al. Does coronary atherosclerosis deserve to be diagnosed early in diabetic patients? The DADDY-D trial. Screening diabetic patients for unknown coronary disease. Eur J Intern Med. 2015; 26:407–13.
Article
40. Lee KY, Hwang BH, Kim TH, Kim CJ, Kim JJ, Choo EH, et al. Computed tomography angiography images of coronary artery stenosis provide a better prediction of risk than traditional risk factors in asymptomatic individuals with type 2 diabetes: a long-term study of clinical outcomes. Diabetes Care. 2017; 40:1241–8.
Article
41. Halon DA, Azencot M, Rubinshtein R, Zafrir B, Flugelman MY, Lewis BS. Coronary computed tomography (CT) angiography as a predictor of cardiac and noncardiac vascular events in asymptomatic type 2 diabetics: a 7-year population-based cohort study. J Am Heart Assoc. 2016; 5:e003226.
Article
42. Guaricci AI, De Santis D, Carbone M, Muscogiuri G, Guglielmo M, Baggiano A, et al. Coronary atherosclerosis assessment by coronary CT angiography in asymptomatic diabetic population: a critical systematic review of the literature and future perspectives. Biomed Res Int. 2018; 2018:8927281.
Article
43. Lee CH, Lee SW, Park SW. Diabetes and subclinical coronary atherosclerosis. Diabetes Metab J. 2018; 42:355–63.
Article
44. Rassi CH, Churchill TW, Tavares CA, Fahel MG, Rassi FP, Uchida AH, et al. Use of imaging and clinical data to screen for cardiovascular disease in asymptomatic diabetics. Cardiovasc Diabetol. 2016; 15:28.
Article
45. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41:255–323.
46. Korean Diabetes Association. Korean 2019 treatment guideline for diabetes [Internet]. Seoul: Korean Diabetes Association;2019. [cited 2020 Jun 14]. Available from: https://www.diabetes.or.kr/pro/publish/guide.php?code=guide&number=735&mode=view#.
47. Katakami N, Mita T, Gosho M, Takahara M, Irie Y, Yasuda T, et al. Clinical utility of carotid ultrasonography in the prediction of cardiovascular events in patients with diabetes: a combined analysis of data obtained in five longitudinal studies. J Atheroscler Thromb. 2018; 25:1053–66.
Article
48. Cardoso CRL, Salles GC, Leite NC, Salles GF. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2019; 18:2.
Article
49. Jeevarethinam A, Venuraju S, Dumo A, Ruano S, Mehta VS, Rosenthal M, et al. Relationship between carotid atherosclerosis and coronary artery calcification in asymptomatic diabetic patients: a prospective multicenter study. Clin Cardiol. 2017; 40:752–8.
Article
50. Akazawa S, Tojikubo M, Nakano Y, Nakamura S, Tamai H, Yonemoto K, et al. Usefulness of carotid plaque (sum and maximum of plaque thickness) in combination with intima-media thickness for the detection of coronary artery disease in asymptomatic patients with diabetes. J Diabetes Investig. 2016; 7:396–403.
Article
51. Jeevarethinam A, Venuraju S, Dumo A, Ruano S, Rosenthal M, Nair D, et al. Usefulness of carotid plaques as predictors of obstructive coronary artery disease and cardiovascular events in asymptomatic individuals with diabetes mellitus. Am J Cardiol. 2018; 121:910–6.
Article
52. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease: executive summary. Endocr Pract. 2017; 23:479–97.
53. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019; 140:e563–95.
Article
54. Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018; 379:633–44.
Article
55. Seferovic PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020; 22:196–213.
Article
56. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019; 140:e294–324.
Article
57. Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20:853–72.
58. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2017; 136:e137–61.
Article
Full Text Links
  • ENM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr